Switzerland (CH)

Embodiment, presence, and their intersections (2020) Beckerle P, Nostadt N, Abbink DA, Christ O Journal article, Review article What is meaningful research and how should we measure it? (2020) Helmer S, Blumenthal DB, Paschen K Journal article White coat adherence effect on glucose control in adult individuals with diabetes (2020) Zueger T, Gloor M, Lehmann V, Melmer A, Kraus M, Feuerriegel S, Laimer M, Stettler C Journal article Secukinumab Significantly Decreased Joint Synovitis Measured by Power Doppler Ultrasonography in Biologic-naive Patients with Active Psoriatic Arthritis: Primary (12-Week) Results from a Randomized, Placebo-Controlled Phase III Study (2020) D'Agostino M, Schett G, Lopez-Rdz A, Senolt L, Maldonado-Cocco J, Burgos-Vargas R, Naredo E, et al. Conference contribution Secukinumab Provides Sustained Improvements in Clinical and Imaging Outcomes in Patients with Psoriatic Arthritis and Axial Manifestations: Results from the MAXIMISE Trial (2020) Baraliakos X, Gossec L, Pournara E, Jeka S, Blanco R, D'Angelo S, Schett G, et al. Conference contribution Machine Learning Identifies an Association Between Pre-existing Radiographic Damage and Long-term Clinical Outcomes with Secukinumab Therapy in Patients with Psoriatic Arthritis (2020) Mease P, Van Der Heijde D, Kirkham B, Schett G, Orbai AM, Ritchlin C, Merola J, et al. Conference contribution Reduced Decline in Forced Vital Capacity in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs) Treated with Nintedanib (2020) Matteson E, Distler O, Distler J, Kuwana M, Pope J, Seibold J, James A, et al. Conference contribution And Thereby Hangs a Tale: A Critical Anatomy of (Popular Tales) (2020) Krug C, Habermann I Edited Volume Frühgeborene an der Grenze der Lebensfähigkeit (Entwicklungsstufe S2k, AWMF-Leitlinien-Register Nr024/019, Juni 2020) (2020) Bührer C, Felderhoff-Müser U, Gembruch U, Hecher K, Kainer F, Kehl S, Kidszun A, et al. Journal article Progression-free survival and overall survival in patients with advanced her2-positive breast cancer treated with trastuzumab emtansine (T-dm1) after previous treatment with pertuzumab (2020) Michel LL, Hartkopf AD, Fasching P, Kolberg HC, Hadji P, Tesch H, Häberle L, et al. Journal article